Mechanisms of oxidative stress and myocardial protection during open-heart surgery

Nikolaos G. Baikoussis, Nikolaos A. Papakonstantinou¹, Chrysoula Verra², Georgios Kakouris², Maria Chounti³, Panagiotis Hountis⁴, Panagiotis Dedeilias, Michalis Argiriou

Department of Cardiovascular and Thoracic Surgery, “Evangelismos” General Hospital of Athens, ¹Department of General Surgery, Agioi Anargiroi General Hospital, Kifissia, ²Department of Thoracic and Cardiovascular Surgery, Athens Naval and Veterans Hospital, Athens, ³Department of Medical Biopathology, Patras General Hospital, ⁴Nursing School - Technological Institute of Patras, Patras, Greece

ABSTRACT

Cold heart protection via cardioplegia administration, limits the amount of oxygen demand. Systemic normothermia with warm cardioplegia was introduced due to the abundance of detrimental effects of hypothermia. A temperature of 32–33°C in combination with tepid blood cardioplegia of the same temperature appears to be protective enough for both; heart and brain. Reduction of nitric oxide (NO) concentration is in part responsible for myocardial injury after the cardioplegic cardiac arrest. Restoration of NO balance with exogenous NO supplementation has been shown useful to prevent inflammation and apoptosis. In this article, we discuss the “deleterious” effects of the oxidative stress of the extracorporeal circulation and the up-to-date theories of “ideal” myocardial protection.

Key words: Cardioplegia; Free radicals; Ischemia-reperfusion syndrome; Myocardial protection; Oxidative stress; Reperfusion injury

INTRODUCTION

Cardiopulmonary bypass (CPB) triggers deleterious effects that may potentially cause dysfunction in almost every organ such as kidney, liver, lungs, central nervous system, and cardiovascular system.[1] Systemic inflammatory response syndrome (SIRS) is considered as the main etiologic factor causing heart damage.[2] It is usually a result of temporary cross clamping myocardial ischemia and the subsequent reperfusion injury after the restoration of heart perfusion.[1]

Figure 1 shows the factors implicated in oxidative stress and their mode of action.

These factors induce oxidative stress via the generation of reactive oxygen species (ROS).[3] ROS, detected as radical adducts or lipid peroxides in coronary venous blood after aortic clamp release, can cause reperfusion injury and affect myocardial recovery.[4,5] Cardioplegia used in CPB also participates in cardiac injury via several ways such as damaging excitation-contraction proteins and limits nitric oxide (NO) bioactivity.[6]

Myocardial protection during CPB is mostly consisted of two components: Hypothermia[7] to diminish oxygen demand, and potassium inducing electromechanical cardiac arrest.[8] The combination of the aforementioned methods has given just a few benefits, and it has been long proved that hypothermia has a detrimental impact on
enzymatic and biochemical systems. Normothermia, although used by just a few surgical teams, limits the risk of postoperative complications. As a consequence, there is a continuing debate as to which is the most secure method for myocardial protection if any. We will try to address this important issue.

DELETERIOUS CARDIOPULMONARY BYPASS-INDUCED EFFECTS

SIRS is induced by CPB via the activation of neutrophils and endothelial cells, as well as inflammatory mediators, such as Factor XII, kallikrein-kinin, fibrinolytic, and complement systems and cytokines. The pro-inflammatory cytokines-tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-8, and the anti-inflammatory cytokine IL-10 are also increased.

Characteristic symptoms of SIRS are fever, elevated white blood cells, respiratory insufficiency, elevated heart rate, and a PaCO₂ < 32 mmHg. Figure 1 shows the main factors responsible for the initiation of the SIRS process. Moreover, inflammation, infarction, and contractile impairment resulting in cardiac dysfunction can be the deleterious effects of reperfusion of the ischemic heart after CPB. Apoptosis of cardiomyocytes can also be induced by ischemia and reperfusion, leading to ventricular dysfunction and subsequent heart failure due to significant loss of myocardial tissue. Myocardial temperature and flow deprivation time are the major factors that indicate whether CPB related myocardial ischemia-reperfusion results in irreversible (myocardial necrosis) or reversible (myocardial stunning) injury. Cardiac-specific troponin I (cTnI) and creatine kinase MB isoenzyme (CK-MB) are the established markers of myocardial necrosis. Patients undergoing coronary artery bypass graft (CABG) have been shown to have elevated cTnI levels as a result of myocardial damage. Handling the myocardium, placing sutures for cannulation and dissecting the myocardium to reveal a coronary vessel also lead to cTnI augmentation. cTnI elevation has been correlated with the quality of myocardial protection. Arterial values over 15 µg/l for cTnI and 30 µg/l for CK-MB demonstrates perioperative myocardial infarction (MI), although 25% of post-CABG patients have a CK-MB mass value >35.8 µg/l without experiencing any ischemic complications. Carrier et al. suggested that postoperative MI is characterized by a value of cTnI in the serum over 39 ng/mL at 24 h postoperatively. However, clinical studies doubt if there is any significant correlation between necrosis and contractile function. Some studies demonstrate very close correlation among cardiac enzymes release, recovery of oxidative metabolism, and ischemic time while others show that there is no such correlation. They conclude that the duration of cardioplegic cardiac arrest (CCA) is not the principal factor of perioperative myocardial damage. An atherosclerosis both quality and route of delivery of cardioplegia and temperature are most likely to be responsible for the myocardial injury. Myocardial stunning seems to be induced by oxidative stress during reperfusion. Activation of neutrophils, poor perfusion of the peripheral tissues and the high oxygen tension used during CPB are responsible for both coronary and systemic oxygen free radical generation after cardioplegia administration. Moreover, peripheral alkyl- and alkoxyl- radicals appear to be released continuously during the cross-clamp period apart from the reperfusion time of the ischemic heart. The existence of a correlation between the severity of oxidative stress and postoperative recovery of cardiac function is also controversial. During reperfusion, heart constitutes a source of ROS production and is also a target of systemic ROS generated by activated cells. ROS including alkyl- and alkoxyl- radicals could exacerbate myocardial ischemia-reperfusion injury, as they are able to participate in cellular injury, affecting myocardial contractility. Among other investigators, support the existence of a relationship between oxidative stress and myocardial dysfunction. But, others did not find such correlation. Karua et al. suggest that CPB-related oxidative stress does not influence the
postoperative myocardial recovery in CABG patients with good preoperative left ventricular function. Finally, a decrease of endogenous NO generation, catalyzed by inducible NO synthase (iNOS), is possible after CPB due to cardioplegia-induced cardiac arrest.[6] Temporary endothelial cell dysfunction results in a lack of NO sufficiency during the reperfusion period of CPB. Subsequently, vasospasm takes place due to low levels of NO.[49] NO appears to participate in the nuclear factor-κB (NF-κB) system,[16] in the evolution of cardiovascular injury[50] and in the anti-inflammatory properties of the vascular endothelium.[51] Lower concentrations of bioavailable NO leads to chronic activation of NF-κB, which is associated with inflammation.[52] NF-κB stimulates the immune system, particularly B cells, and macrophages. Cytokines and oxygen radicals activate the aforementioned cells resulting in NF-κB translocation. Alterations in NF-κB system are determinants for the deleterious effects of CCA during CPB.[6] Yeh et al.[6] proved that CCA under CPB induced a reduction of myocardial NO concentration with a subsequent increase of NF-κB translocation. A similar change was demonstrated concerning the expression of NF-κB-mediated genes.

MYOCARDIAL PROTECTION

The basic role of myocardial protection during cardiac surgery is a balance between a bloodless, motionless operating field and the maintenance of the myocardial function.[9] Hypothermia or normothermia can be both used for CPB.[2] Provided that the myocardium constitutes a source of cytokines,[53,54] both perfusion temperatures of CPB and cardioplegia type are able to affect the generation of inflammatory mediators, such as IL-6 and TNF-α.[5] Cardioplegia induces electromechanical arrest. Therefore, myocardial metabolism is reduced, and intermittent ischemia is bearable.[55,56] The optimal choice of cardioplegia, though, is controversial. In the UK, 56% of surgeons performing on-pump CABG prefer cold blood cardioplegia, 14% of them prefer warm blood cardioplegia and 14% use crystalloid cardioplegia, whereas retrograde infusion is the method of choice for 21% of them. The rest 16% of surgeons apply cross-clamp fibrillation, avoiding any type of cardioplegia.[57] A retrospective review[58] studied 22 papers with equal to or over 50 patients each with respect to types of cardioplegia, Guru et al.[59] reported a correlation of blood cardioplegia with significantly lower CK-MB levels and significantly fewer cases of low output syndrome in their meta-analysis of 34 randomized trials. Øvrum et al.[60] demonstrated no clinical differences among 1440 patients undergoing either antegrade cold blood or crystalloid cardioplegia, whereas Martin et al.[61] never completed their 1001 patients study comparing warm blood to cold crystalloid cardioplegia because of a high incidence of neurological complications associated with the former. Ten of the rest 19 studies showed that blood cardioplegia was superior to crystalloid cardioplegia in terms of statistically significant clinical effects. Five of them also demonstrated the superiority of the former with regard to enzyme release.[62] Barra et al.[63] reported a linear correlation of the cold crystalloid antegrade cardioplegia with the perioperative MI risk, elevated by four times. Despite its efficacy in causing electromechanical arrest, hyperkalemic crystalloid cardioplegia is only partially cardioprotective.[63] Ventricular dysfunction after cardioplegia infusion is possible potentially due to postoperative cardiomyocyte apoptosis.[63,64] Blood has a lot of superior properties that make its substance unique to be compared to crystalloid.[65] Retrograde cardioplegia has been proved to efficiently provide myocardial protection.[66] Nevertheless, it is not protective enough for the interventricular septum and the right ventricle[67] due to anatomical variations of the coronary vascular bed.[68] On the other hand, antegrade hyperkalemic warm blood infusion permits diastolic cardiac arrest and preserves high energy phosphate levels.[69] At the present time, potassium infusion, providing a nonbeating heart due to the electromechanical cardiac arrest caused, and hypothermia, providing low oxygen needs, are the axis of myocardial protection.[9]

Benefits gained by hypothermia

It was in the 1960s that hypothermic cardioplegia was firstly introduced. It showed the result of decreasing myocardial metabolism, which was determinant for myocardial protection against ischemia.[70] Systemic hypothermia leads to hypothermia of the heart, as well as to repression of myocardial oxygen consumption.[71] When the myocardial temperature is low its metabolism tends to be as low as well.[72-74] In conclusion, the electromechanical arrest is responsible for a 90% reduction in oxygen consumption.[9] Although hypothermia further reduces myocardial oxygen consumption, it offers a minor additional benefit in the order of 7%.[55,73]

DELETERIOUS EFFECTS OF HYPOTHERMIA

Despite reducing metabolic activity, hypothermia induces many detrimental effects.[9,76] It has an adverse impact
of blood cardioplegia containing high levels of potassium and it is preserved by low potassium blood cardioplegia infusion during the rest of the cross-clamp time. The latter is also useful as a continuous source of oxygen for the normothermic myocardium. However, during coronary anastomosis, the infusion of blood cardioplegia must be temporarily stopped, so as for a bloodless operating field to be provided. Active continuous rewarming is also necessary to achieve systemic normothermia, meaning a temperature equal to 37°C, as the body temperature lowers in the operating room. Either retrograde or antegrade warm blood cardioplegia can be used to achieve warm heart protection. Lots of benefits are obtained by normothermia. Firstly, continuous warm blood administration provides a constant oxygen supply preserving aerobic metabolism. Better tissue oxygen transfer is also achieved thanks to the near normal hemoglobin affinity for oxygen, normal enzymatic activity, and normal erythrocyte deformability. Viscosity is also maintained by normothermia. Furthermore, as the skin is warmed under normothermia, the adrenergic response is minimized, thus diminishing the afterload and elevating the cardiac index. Additionally, the complications caused by high PaO₂ are prevented using normothermia permitting the control of PaO₂. Ischemia-reperfusion injury from free radicals is avoided as aerobic cardioplegic perfusion takes place. Neither intracellular pH nor the acid-basic balance is affected resulting in the better gas transfer. Ionic status and water homeostasis are also preserved thanks to the normal supply of adenosine triphosphate to ion pumps. Moreover, spontaneous defibrillation after cross-clamp release is more possible, and MI tends to be less common when CPB is performed under warm heart protection. Finally, normothermia may decrease the CPB-related inflammatory response. Apart from Lichtenstein et al. who highlighted the clinical benefit of normothermia, particularly in prolonged aortic cross-clamp time (6.5 h), Bert et al. also reported data favouring normothermia against hypothermia with regard to postoperative clinical outcomes. Lots of other studies demonstrate a superiority of systemic and myocardial temperature preservation. Tavares-Murta et al. compared 10 patients who were submitted to CPB under hypothermia (29–31°C) with crystalloid cardioplegia (HC group) to 10 other patients who received normothermic (36.5–37°C) CPB with blood cardioplegia (NB group). All of them presented elevated cytokine levels, but this change took place earlier and for a longer time in HC group. The same group had significantly higher peak levels of IL-6, which were significantly correlated (P < 0.01) with peak levels of IL-8. NO generation was also decreased in HC group. Moreover, two groups of patients were compared by

**BENEFICIAL EFFECTS OF NORMOTHERMIA WITH WARM CARDIOPLEGIA**

As a result of the aforementioned mechanisms, continuous normothermic blood cardioplegia has been introduced. Lichtenstein et al. studying 720 patients who underwent CABG under normothermia, showed that normothermic electromechanical arrest was well tolerated for over 15 min by the myocardium. Normothermic myocardial protection is achieved by the continuous administration of hyperkalemic normothermic blood during the aortic cross-clamp time. According to Lichtenstein et al., continuous hyperkalemic blood infusion preserving cardiac arrest and providing oxygen for the normothermic myocardium offers adequate myocardial protection throughout the cardiac surgery. Cardiac arrest is achieved by the infusion of blood cardioplegia containing high levels of potassium and it is preserved by low potassium blood cardioplegia infusion during the rest of the cross-clamp time. The latter is also useful as a continuous source of oxygen for the normothermic myocardium. However, during coronary anastomosis, the infusion of blood cardioplegia must be temporarily stopped, so as for a bloodless operating field to be provided. Active continuous rewarming is also necessary to achieve systemic normothermia, meaning a temperature equal to 37°C, as the body temperature lowers in the operating room. Either retrograde or antegrade warm blood cardioplegia can be used to achieve warm heart protection. Lots of benefits are obtained by normothermia. Firstly, continuous warm blood administration provides a constant oxygen supply preserving aerobic metabolism. Better tissue oxygen transfer is also achieved thanks to the near normal hemoglobin affinity for oxygen, normal enzymatic activity, and normal erythrocyte deformability. Viscosity is also maintained by normothermia. Furthermore, as the skin is warmed under normothermia, the adrenergic response is minimized, thus diminishing the afterload and elevating the cardiac index. Additionally, the complications caused by high PaO₂ are prevented using normothermia permitting the control of PaO₂. Ischemia-reperfusion injury from free radicals is avoided as aerobic cardioplegic perfusion takes place. Neither intracellular pH nor the acid-basic balance is affected resulting in the better gas transfer. Ionic status and water homeostasis are also preserved thanks to the normal supply of adenosine triphosphate to ion pumps. Moreover, spontaneous defibrillation after cross-clamp release is more possible, and MI tends to be less common when CPB is performed under warm heart protection. Finally, normothermia may decrease the CPB-related inflammatory response. Apart from Lichtenstein et al. who highlighted the clinical benefit of normothermia, particularly in prolonged aortic cross-clamp time (6.5 h), Bert et al. also reported data favouring normothermia against hypothermia with regard to postoperative clinical outcomes. Lots of other studies demonstrate a superiority of systemic and myocardial temperature preservation. Tavares-Murta et al. compared 10 patients who were submitted to CPB under hypothermia (29–31°C) with crystalloid cardioplegia (HC group) to 10 other patients who received normothermic (36.5–37°C) CPB with blood cardioplegia (NB group). All of them presented elevated cytokine levels, but this change took place earlier and for a longer time in HC group. The same group had significantly higher peak levels of IL-6, which were significantly correlated (P < 0.01) with peak levels of IL-8. NO generation was also decreased in HC group. Moreover, two groups of patients were compared by
Bical et al.\textsuperscript{[102]} using warm blood protection in Group I and cold blood protection in Group II with intermittent antegrade cardioplegia in both groups. They reported higher levels of coronary sinus lactate at cross-clamp removal in Group I, while more myoglobin was generated after reperfusion in Group II. Troponin I levels were also higher in Group II. Thus, warm cardioplegia protection was better than cold.

**ADDITIONAL BENEFITS OF TEPID (32°C) CARDIOPLEGIA**

The safe duration of a cardioplegia break under normothermia is unclear, so tepid cardioplegia constitutes an alternative choice.\textsuperscript{[101,103]} It has the ability to protect the myocardium even during cardioplegia interruptions apart from effectively promoting aerobic metabolism.\textsuperscript{[70]} Comparing this type of cardioplegia with warm blood cardioplegia, the myocardial oxygen consumption is similar, while anaerobic lactate and acid washout is less during the former.\textsuperscript{[104]} Furthermore, during lukewarm ( tepid) blood cardioplegia more glucose and oxygen are consumed by the myocardium, whereas less lactate is generated than during cold cardioplegia.\textsuperscript{[70]} Moreover, although warmth protects the heart, it negatively affects the brain.\textsuperscript{[105]} Warm blood cardioplegia is commonly used under systemic normothermia, which raises the hazard of cardiac surgery-associated neurological disorders.\textsuperscript{[70]} Hvass and Depoix\textsuperscript{[106]} demonstrated no increase in neurological disorders at 37°C. In a study published in Lancet in 1994,\textsuperscript{[107]} exanimating 1732 patients operated under lower systemic temperature, found no significant difference neither concerning the myocardium nor the incidence of neurological disorders. Martin et al.\textsuperscript{[61]} and Guyton et al.\textsuperscript{[108]} comparing 493 patients who underwent CABG under warm blood cardioplegia and a systemic temperature of 35°C with a series of 508 patients who were operated under cold cardioplegia (8°C) and a systemic temperature of 28°C found similar results with regard to perioperative infarction, mortality, and intra-aortic counterpulsation requirement, respectively. Nevertheless, as far as neurological complications were concerned, they were significantly more frequent in the normothermic group (4.5%) than in the cold one (1.4%). A systemic temperature of 32–33°C combined with lukewarm blood cardioplegia seems to be more protective for the cerebrum overcoming the hazard of neurologic complications under normothermic conditions.\textsuperscript{[9,70,100]} Apart from not influencing the neurologic system and preserving physiological and enzymatic systems, tepid (32°C) protection is superior to cold protection in terms of reduced ventricular rhythm disorders, spontaneous defibrillation and blood loss.\textsuperscript{[91,99,102]} Moreover, prolongation of the aortic cross-clamp time without worsening operative mortality and morbidity can be achieved via continuous retrograde lukewarm blood cardioplegia under systemic normothermia.\textsuperscript{[86]} Less myocardial injury and better functional recovery of the left ventricle constitute additional benefits gained by tepid cardioplegia.\textsuperscript{[70]} Continuous tepid blood cardioplegia is advantageous in preventing cardiomyocytes from apoptosis and maintaining coronary endothelium integrity. Myocardial injury induced by cardiac arrest and endothelial dysfunction due to reperfusion injury are minimized by this type of cardioplegia thanks to adequate supply of nutrients and oxygen and the concomitant washout of all the metabolic waste.\textsuperscript{[63]} Engelman et al.\textsuperscript{[110]} compared three groups undergoing coronary surgery: Group I - cold (20°C systemic temperature, 8–10°C blood cardioplegia), Group II - tepid (32°C systemic temperature, 32°C blood cardioplegia), and Group III - warm (37°C systemic temperature, 37°C blood cardioplegia). No death was noticed in either of these groups. Group I was associated with a more prolonged hospital stay and a postoperative CK-MB increase. Neurological complications were significantly lower in the tepid group (2%) against the 18.9% percentage of the cold group and 9.3% in one of the warm group. In Badak et al.’s study,\textsuperscript{[70]} comparing tepid with cold blood cardioplegia during CABG, 30 patients were randomized into two groups of 15 patients (a tepid and a cold one). The tepid group was characterized by greater myocardial oxygen extraction, greater oxygen and glucose consumption, and lower lactate generation than the cold one. In the early post-CPB period, the left ventricular stroke work index was also greater in the tepid group and the early postoperative CK-MB levels at 6, 12, and 24 h were significantly lower than in the cold group. Finally, significantly more patients submitted to cold heart protection needed defibrillation compared to those undergone tepid heart protection. In a recent review study conducted by Zeng et al. in 2014,\textsuperscript{[111]} has been showed that cold blood cardioplegia reduces perioperative MI when compared with cold crystalloid cardioplegia. No differences in the overall incidence rates of spontaneous sinus rhythm, mortality (within 30 days), atrial fibrillation, or stroke were observed.

**ROLE OF NITRIC OXIDE IN MYOCARDIAL PROTECTION**

NO participates in several ways in the vascular bed.\textsuperscript{[112]} It causes vasodilation on vascular smooth muscles via
activation of soluble guanylyl cyclase and subsequent cyclic guanosine monophosphate formation. Adhesion, inflammation, and proliferation of endothelial cells are also inhibited by NO. Therefore, exogenous NO supplementation also plays a significant role in myocardial protection by restoring NO concentration diminished by CCA under CPB.\(^\text{[111]}\) Multiple benefits can be obtained by restoration of NO concentration including repression of the NF-κB translocation and reduction of the generation of inflammatory cytokines.\(^\text{[6]}\) NO donor throughout reperfusion limits myocardial injury and the inflammatory response (lower IL-6, IL-8 and TNF-α levels).\(^\text{[113]}\) Additionally, NO donor prevents the apoptosis of cardiomyocytes and preserves their contractile function.\(^\text{[6]}\) Lower levels of markers of myocardial damage are also noticed after the infusion of blood cardioplegia enriched with the substrate for NO synthesis L-arginine.\(^\text{[111]}\) Experiments have recently been conducted to investigate the cardioprotective role of oxytocin,\(^\text{[113]}\) “h ANP shot” using human atrial natriuretic peptide\(^\text{[114]}\) and the use of statin and angiotensin receptor blocker;\(^\text{[115]}\) Cardioprotection and lung protection is also the “cornerstone” for a successful open heart intervention.\(^\text{[116]}\)

**CONCLUSIONS**

It is obvious that CPB itself, as well as CCA under CPB have some detrimental impacts on the myocardium. However, which is the ideal myocardial protection? In spite of the cardioprotective properties of cold heart protection thanks to limiting the needs in oxygen, systemic normothermia with warm cardioplegia was introduced due to the abundance of detrimental effects of hypothermia. Nevertheless, although normothermia is the best choice for heart protection, it is not for the brain. A temperature of 32–33°C in combination with tepid blood cardioplegia of the same temperature appears to be protective enough for both of them making the procedure less invasive and permitting cost reduction too. In addition, since the reduction of NO concentration is in part responsible for myocardial injury after CCA under CPB, the restoration of NO balance with exogenous NO supplementation is ultimately useful to prevent inflammation and apoptosis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Clermont G, Vergely C, Jazayeri S, Lahet JJ, Goudeau JJ, Lecour S, et al. Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology 2002;96:80-7.
2. Tavares-Murta BM, Cordeiro AO, Murta EF, Cunha Fde Q, Bisinotto FM. Effect of myocardial protection and perfusion temperature on production of cytokines and nitric oxide during cardiopulmonary bypass. Acta Cir Bras 2007;22:243-50.
3. Berg K, Haaverstad R, Astudillo R, Bjørngaard M, Skarre S, Wiseth R, et al. Oxidative stress during coronary artery bypass operations: Importance of surgical trauma and drug treatment. Scand Cardiovasc J 2006;40:291-7.
4. Ulus AT, Aksoyek A, Ozkan M, Katircioglu SF, Basu S. Cardiopulmonary bypass as a cause of free radical-induced oxidative stress and enhanced blood-borne isoprostanes in humans. Free Radic Biol Med 2003;34:911-7.
5. Goudeau JJ, Clermont G, Guillery O, Lemaire-Ewing S, Musat A, Vernet M, et al. In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress. J Cardiovasc Pharmacol 2007;49:39-45.
6. Yeh CH, Chen TP, Lee CH, Wu YC, Lin YM, Lin PJ. Cardioplegia-induced cardiac arrest under cardiopulmonary bypass decreased nitric oxide production which induced cardiomyocytic apoptosis via nuclear factor kappa B activation. Shock 2007;27:422-8.
7. Bigelow WG, Lindsay WK, Greenwood W.F. Hypothermia: its possible role in cardiac surgery: An investigation of factors governing survival in dogs at low body temperatures. Ann Surg 1950;132:849-66.
8. Melrose DG, Dieger DB, Bentall HH, Belzer FO. Elective cardiac arrest: Preliminary communications. Lancet 1955;2:21-2.
9. Gaillard D, Bical O, Paumier D, Trivin F. A review of myocardial normothermia: Its theoretical basis and the potential clinical benefits in cardiac surgery. Cardiovasc Surg 2000;8:198-203.
10. Faymonville ME, Pincemail J, Duchateau J, Paulus JM, Adam A, Deby-Dupont G, et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991;102:309-17.
11. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
12. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:355-66.
13. Kawamura T, Nara N, Kadosaki M, Inada K, Endo S. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med 2000;28:2201-8.
14. Volk T, Schmutzler M, Engelhardt L, Döcke WD, Volk HD, Konertz W, et al. Influence of aminosteroid and glucocorticoid treatment on inflammation and immune function during cardiopulmonary bypass. Crit Care Med 2001;29:2137-42.
Baikoussis, et al.: Myocardial metabolism and oxidative stress during heart operations

15. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:715-20.

16. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-37.

17. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 1995;92:8031-5.

18. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.

19. Didenko VV, Wang X, Yang L, Hornsby PJ. Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. J Clin Invest 1996;97:1723-31.

20. Saraste A, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997;95:320-3.

21. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-34.

22. Benoit MO, Paris M, Sillner J, Fiemeyer A, Moatti N. Cardiac troponin I: Its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Crit Care Med 2001;29:1880-6.

23. Nesher N, Zisman E, Wolf T, Sharyon R, Bolotin G, David M, et al. Strict thermoregulation attenuates myocardial injury during coronary artery bypass graft surgery as reflected by reduced levels of cardiac-specific troponin I. Anesth Analg 2003;96:328-35.

24. Bonnefoy E, Filley S, Kirkorian G, Guidollet J, Roriz R, Robin J, et al. Troponin I, troponin T, or creatine kinase-MB to detect perioperative myocardial damage after coronary artery bypass surgery. Chest 1998;114:482-6.

25. Alyanakian MA, Dehoux M, Chatel D, Seguret C, Desmonts JM, Durand G, et al. Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth 1998;12:288-94.

26. Holmvang L, Jurlander B, Rasmussen C, Thiel JJ, Grande P, Clemmensen P. Use of biochemical markers of infarction for diagnosing perioperative myocardial infarction and early graft occlusion after coronary artery bypass surgery. Chest 2002;121:103-11.

27. Carrier M, Pellerin M, Perrault LP, Solymos BC, Pelletier LC. Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg 2000;69:435-40.

28. Chang PP, Sussman MS, Conte JV, Grega MA, Schulman SP, Gerstenblith G, et al. Postoperative ventricular function and cardiac enzymes after on-pump versus off-pump CABG surgery. Am J Cardiol 2002;89:1107-10.

29. Kwinecki J, Jemiolity M, Czepczynski R, Baszko A, Ruchala M, Sosinski J, et al. Nuclear imaging techniques in the assessment of myocardial perfusion and function after CABG surgery: Does it correlate with CK-MB elevation? Nucl Med Rev Cent East Eur 2003;6:5-9.

30. Koh TW, Hooper J, Kemp M, Ferdinand FD, Gibson DG, Pepper JR. Intraoperative release of troponin I in coronary venous and arterial blood and its relation to recovery of left ventricular function and oxidative metabolism following coronary artery surgery. Heart 1998;80:341-8.

31. Karua I, Loita R, Paapstel A, Kairane C, Zilmer M, Starkopf J. Early postoperative function of the heart after coronary artery bypass grafting is not predicted by myocardial necrosis and glutathione-associated oxidative stress. Clin Chim Acta 2005;359:195-202.

32. Raman JS, Bellomo R, Hayhoe M, Tsamitros M, Buxton BF. Metabolic changes and myocardial injury during cardioplegia: A pilot study. Ann Thorac Surg 2001;72:1566-71.

33. Biagioli B, Borrelli E, Maccherini M, Bellomo G, Lisi G, Giomarelli P, et al. Reduction of oxidative stress does not affect recovery of myocardial function: Warm continuous versus cold intermittent blood cardioplegia. Heart 1997;77:465-73.

34. Morse D, Adams D, Maganoni B. Platelets and neutrophil activation during cardiac surgical procedures: Impact of cardiopulmonary bypass. Ann Thorac Surg 1998;65:691-5.

35. Ihunken K, Winkler A, Schlessak C, Sarai K, Neidhart G, Unkelbach U, et al. Normoxic cardiopulmonary bypass reduces oxidative myocardial damage and nitric oxide during cardiac operations in the adult. J Thorac Cardiovasc Surg 1998;116:327-34.

36. Knight PR, Holm BA. The three components of hyperoxia. Anesthesiology 2000;93:3-5.

37. Dhotep-Burger P, Vuilleminot A, Lecompte T, Pasquier C, Bara L, Julia P, et al. Neutrophil degranulation related to the reperfusion of ischemic human heart during cardiopulmonary bypass. J Cardiovasc Pharmacol 1995;25:5124-9.

38. Hansen PR, Stawski G. Neutrophil mediated damage to isolated myocytes after anoxia and reoxygenation. Cardiovasc Res 1994;28:565-9.

39. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-85.

40. Hearse DJ, Bolli R. Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Cardiovasc Res 1992;26:101-8.

41. Bolli R. Mechanism of myocardial “stunning”. Circulation 1990;82:723-38.

42. Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989;80:1049-62.

43. Li XY, McCay PB, Zughib M, Jeroudi MO, Triana JF, Bolli R. Demonstration of free radical generation in the “stunned” myocardium in the conscious dog and identification of major differences between conscious and open-chest dogs. J Clin Invest 1993;92:1025-41.

44. Bradamante S, Monti E, Faraci C, Lazzarini E, Miccini E. Protective activity of the spin trap tert-butyl-alpha-phenyl nitronate (PBN) in reperfused rat heart. J Mol Cell Cardiol 1992;24:375-86.

45. Ferrari R, Alfieri O, Curello S, Ceconi C, Cargnoni A, Alfieri S, et al. Relation between left ventricular function and oxidative stress in patients undergoing bypass surgery. Heart 1998;79:242-7.
Oxygen transport and utilization in dogs at low body temperatures. Am J Physiol 1950;160:125-30.

78. Dobbs WA, Engelman RM, Rousou JH, Pels MA, Alvarez JM. Residual metabolism of the hypothermic-arrested pig heart. J Surg Res 1981:31:319-23.

79. Lyons J, Raison J. A temperature-induced transition in mitochondrial oxidation: Contrasts between cold and warmblooded animals. Comp Biochem Physiol 1970;37:405-11.

80. Reissmann K, VanCitters R. Oxygen consumption and mechanical efficiency of the hypothermic heart. J Appl Physiol 1956;9:427-32.

81. Teoh KH, Christakis GT, Weisel RD, Frenses SE, Mickle DA, Romaschin AD, et al. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia. J Thorac Cardiovasc Surg 1986;91:888-95.

82. Morita K, Ihnken K, Buckberg GD, Sherman MP, Young HH. Studies of hypoxemic/reoxygenation injury: Without aortic clamping. IX. Importance of avoiding perioperative hyperoxemia in the setting of previous cyanosis. J Thorac Cardiovasc Surg 1995;110 (4 Pt 2):1235-44.

83. Maccherini M, Davoli G, Sani G, Rossi P, Giani S, Lisi G, et al. Warm heart surgery eliminates diaphragmatic paralysis. J Card Surg 1995;10:255-67.
vascular biology to clinical applications. Am J Cardiol 2002;90:40L-8L.
113. Moghimian M, Faghihi M, Karimian SM, Imani A, Houshmand F, Azizi Y. Role of central oxytocin in stress-induced cardioprotection in ischemic-reperfused heart model. J Cardiol 2013;61:79-86.
114. Osaka S, Sezai A, Wakui S, Shimura K, Taniguchi Y, Hata M, et al. Experimental investigation of “hANP shot” using human atrial natriuretic peptide for myocardial protection in cardiac surgery. J Cardiol 2012;60:66-71.
115. Sohma R, Inoue T, Abe S, Taguchi I, Kikuchi M, Toyoda S, et al. Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. J Cardiol 2012;59:91-6.
116. Apostolakis EE, Koletsis EN, Baikoussis NG, Siminelakis SN, Papadopoulos GS. Strategies to prevent intraoperative lung injury during cardiopulmonary bypass. J Cardiothorac Surg 2010;5:1.